These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1790421)

  • 21. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia.
    Seeman E; Devogelaer JP; Lorenc R; Spector T; Brixen K; Balogh A; Stucki G; Reginster JY
    J Bone Miner Res; 2008 Mar; 23(3):433-8. PubMed ID: 17997711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women.
    Oglesby AK; Minshall ME; Shen W; Xie S; Silverman SL
    J Rheumatol; 2003 Jul; 30(7):1579-83. PubMed ID: 12858462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The relationship between quantitative ultrasound and osteoporosis self-assessment tool for Asians (OSTA) score and non-vertebral fracture in postmenopausal Chinese women].
    Tao B; Liu JM; Li XY; Wang JG; Wang WQ; Zhou HF; Guo HF; Wen Y; Zhou WW; Du PF; Ning G
    Zhonghua Nei Ke Za Zhi; 2006 Dec; 45(12):988-91. PubMed ID: 17326996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.
    Maricic M; Adachi JD; Sarkar S; Wu W; Wong M; Harper KD
    Arch Intern Med; 2002 May; 162(10):1140-3. PubMed ID: 12020184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
    Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
    Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women.
    El Maghraoui A; Rezqi A; El Mrahi S; Sadni S; Ghozlani I; Mounach A
    BMC Endocr Disord; 2014 Dec; 14():93. PubMed ID: 25492884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study.
    Salaffi F; Cimmino MA; Malavolta N; Carotti M; Di Matteo L; Scendoni P; Grassi W;
    J Rheumatol; 2007 Jul; 34(7):1551-60. PubMed ID: 17516618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved vertebral fracture threshold in postmenopausal osteoporosis by radiogrametric measurements: its usefulness in selection for preventive therapy.
    Meema HE
    J Bone Miner Res; 1991 Jan; 6(1):9-14. PubMed ID: 2048436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
    Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
    Cummings SR; Black DM; Thompson DE; Applegate WB; Barrett-Connor E; Musliner TA; Palermo L; Prineas R; Rubin SM; Scott JC; Vogt T; Wallace R; Yates AJ; LaCroix AZ
    JAMA; 1998 Dec 23-30; 280(24):2077-82. PubMed ID: 9875874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vertebral fracture: a major risk factor for osteoporosis].
    Krieg MA; Lamy O
    Praxis (Bern 1994); 2004 Feb; 93(9):321-8. PubMed ID: 15060973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma periostin associates significantly with non-vertebral but not vertebral fractures in postmenopausal women: Clinical evidence for the different effects of periostin depending on the skeletal site.
    Kim BJ; Rhee Y; Kim CH; Baek KH; Min YK; Kim DY; Ahn SH; Kim H; Lee SH; Lee SY; Kang MI; Koh JM
    Bone; 2015 Dec; 81():435-441. PubMed ID: 26297442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures.
    Nevitt MC; Cummings SR; Stone KL; Palermo L; Black DM; Bauer DC; Genant HK; Hochberg MC; Ensrud KE; Hillier TA; Cauley JA
    J Bone Miner Res; 2005 Jan; 20(1):131-40. PubMed ID: 15619679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures.
    Oleksik AM; Ewing S; Shen W; van Schoor NM; Lips P
    Osteoporos Int; 2005 Aug; 16(8):861-70. PubMed ID: 15558238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
    Felsenberg D; Miller P; Armbrecht G; Wilson K; Schimmer RC; Papapoulos SE
    Bone; 2005 Nov; 37(5):651-4. PubMed ID: 16126016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin D receptor gene polymorphisms, bone mass, bone loss and prevalence of vertebral fracture: differences in postmenopausal women and men.
    Gómez C; Naves ML; Barrios Y; Díaz JB; Fernández JL; Salido E; Torres A; Cannata JB
    Osteoporos Int; 1999; 10(3):175-82. PubMed ID: 10525708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.